Cixutumumab
Based on 1 Customer Validation
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 947687-12-9
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IGF1R/CD221
In Vitro
Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CHLA-9, TC-71, Rh41 cells
-
Concentration:0.01-100 nM
-
Incubation Time:96 h
-
Result:Inhibited CHLA-9, TC-71and Rh41 cells growth with IC50 values of 49.31, 0.66 and 0.04 nM, respectively.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CB17SC-M scid-/- female mice (solid tumor xenografts model)[1].
-
Dosage:1 mg/rat
-
Administration:Intraperitoneal injection; twice weekly for 6 weeks.
-
Result:Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IGF-I R Protein, Human can bind Cixutumumab. The EC50 for this effect is 2.853 ng/mL. -
Flow cytometric analysis of 1X106 MCF-7 cells with Cixutumumab (HY-P99189, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 947687-12-9
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Cixutumumab]
-
Synonyms
IMC-A12; NSC742460
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)